Detail akcie NovoCure NPV online

Business Summary: NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Novocure Ltd revenues increased 9% to $313.8M. Net loss increased 3% to $74.5M. Revenues reflect France segment increase from $14.3M to $36.3M, Germany segment increase of 23% to $37.8M, Japan segment increase of 18% to $18.2M. Higher net loss reflects Proprietary platform technology segment loss increase of 3% to $77.4M. Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.67.